信立泰：SAL0150片用于肥胖或超重等的临床试验申请获受理

Core Viewpoint - The company, Xinlitai (002294), has received approval from the National Medical Products Administration for its clinical trial application for the innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1]. Group 1 - The clinical trial application for SAL0150 has been officially accepted [1]. - SAL0150 is developed for the treatment of type 2 diabetes and its complications, along with obesity or overweight [1].